Patent Assignment
Reel/Frame 068173/0155
Security Agreement
Recorded: 2024-07-26
Pages: 24
Assignors
CAVION, INC.
Executed: 2024-07-24
CELATOR PHARMACEUTICALS, INC.
Executed: 2024-07-24
GW PHARMA LIMITED
Executed: 2024-07-24
JAZZ PHARMACEUTICALS, INC.
Executed: 2024-07-24
JAZZ PHARMACEUTICALS IRELAND LIMITED
Executed: 2024-07-24
JAZZ PHARMACEUTICALS RESEARCH UK LIMITED (F/K/A GW RESEARCH LIMITED)
Executed: 2024-07-24
Assignee
U.S. BANK TRUST COMPANY, NATIONAL ASSOCIATION, AS COLLATERAL TRUSTEE
100 WALL STREET, SUITE 600, NEW YORK, NEW YORK, 10005
Covered Properties
(122)
Inhibiting Ataxia Telangiectasia and RAD3-Related Protein (Atr)
Application:
18/460,047 →
Publication:
US US20230416236A1
Method of Treating Posttraumatic Stress Disorder
Application:
18/294,129 →
Publication:
US US20240335441A1
Use of Cannabidiol in the Treatment of Epilepsy
Application:
18/292,844 →
Publication:
US US20250025482A1
Methods for Preparing Liposomal Formulations
Application:
18/579,824 →
Publication:
US US20240350411A1
Use of Cannabidiol in the Treatment of Nocturnal Snoring
Application:
18/545,754 →
Publication:
US US20240261234A1
Sulfonamide Orexin Receptor Agonists and Uses Thereof
Application:
18/571,860 →
Publication:
US US20240360081A1
Use of Cannabinoids in the Treatment of Epilepsy
Application:
18/526,795 →
Publication:
US US20240165048A1
Method of Treating Essential Tremor
Application:
18/563,101 →
Publication:
US US20240238261A1
Fused Bicyclic Raf Inhibitors and Methods for Use Thereof
Resorcinol Derivative as a Pharmaceutically Active Compound and Method of Preparation Thereof
Application:
18/560,346 →
Publication:
US US20240238218A1
Rescorcinols, Methods for Their Manufacture, and Uses Thereof
Application:
18/560,341 →
Publication:
US US20240254066A1
Derivatives of Cannabidiol-C4 for the Treatment of Epilepsy
Application:
18/560,337 →
Publication:
US US20240254072A1
6-Hydroxy-Cannabidiol-C4
Application:
18/560,316 →
Publication:
US US20240360060A1
Orexin Receptor Agonists and Uses Thereof
Application:
18/558,245 →
Publication:
US US20240254143A1
Pharmaceutical Composition Comprising a Cannabinoid
Application:
18/477,467 →
Publication:
US US20240226032A9
Modified L-Asparaginase
Application:
18/471,899 →
Publication:
US US20240076643A1
Use of Cannabidiol in the Treatment of Seizures Associated with Rare Epilepsy Syndromes Related to Genetic Abnormalities
Application:
18/005,961 →
Publication:
US US20230277563A1
Use of Cannabidiol in the Treatment of Seizures Associated with Rare Epilepsy Syndromes Related to Genetic Abnormalities
Application:
18/005,960 →
Publication:
US US20230277562A1
Use of Cannabidiol and Clobazam in the Treatment of Childhood-Onset Epilepsy Syndromes
Application:
18/548,003 →
Publication:
US US20250319107A1
Use of Cannabidivarin in the Treatment of Seizures Associated with Canine Epilepsy
Application:
18/546,254 →
Publication:
US US20240226123A9
Cannabidiol Preparations and Its Uses
Application:
18/446,405 →
Publication:
US US20240207220A1
Biaryl Ether Urea Compounds
Application:
18/353,770 →
Publication:
US US20240024313A1
Methods of Use of a Liposomal Composition Comprising an Atr Inhibitor
Application:
63/513,749 →
Combinations Comprising an Atr Inhibitor and a Parp Inhibitor and Methods of Use Thereof
Application:
63/513,744 →
Identification and Treatment of Patients with Epilepsy
Application:
18/258,485 →
Publication:
US US20240301494A1
Cannabinoid Derivative as a Pharmaceutically Active Compound and Method of Preparation Thereof
Cannabinoid Derivatives as Pharmaceutically Active Compounds and Method of Preparation Thereof
Application:
18/257,373 →
Publication:
US US20240025858A1
A Method for Evaluating the Pro-or Anti Convulsive Properties of Test Compounds
Application:
18/257,479 →
Publication:
US US20240215910A1
Use of Cannabidiol in the Treatment of Seizures Associated with Epilepsy Syndromes in Patients Taking Brivaracetam
Application:
18/256,307 →
Publication:
US US20240050452A1
Use of Cannabinoids in the Treatment of Epilepsy
Assays and Methods for Selecting a Treatment Regimen for a Subject with Leukemia
Application:
18/316,719 →
Publication:
US US20230279503A1
Use of Cannabinoids in the Treatment of Angelman Syndrome
Treatment Methods Using Ghb
Application:
18/031,994 →
Publication:
US US20230390228A1
Sodium Oxybate to Treat Idiopathic Hypersomnia
Use of Cannabinoids in the Treatment of Epilepsy
Cannabinoids for Use in the Treatment of Epilepsy
Application:
18/245,856 →
Publication:
US US20240016819A1
Use of Cannabidivarin in the Treatment of Seizures Associated with Rare Epilepsy Syndromes Related to Genetic Abnormalities
Application:
18/044,941 →
Publication:
US US20230346809A1
Cannabidiol Preparations and Its Uses
Fused Bicyclic Raf Inhibitors and Methods for Use Thereof
Modified L-Asparaginase
7-Oh-Cannabidiol (7-Oh-Cbd) and/or 7-Oh-Cannabidivarin (7-Oh-Cbdv) for Use in the Treatment of Epilepsy
Inhibiting Ataxia Telangiectasia and RAD3-Related Protein (Atr)
Use of Cannabinoids in the Treatment of Epilepsy
Assays and Methods for Selecting a Treatment Regimen for a Subject with Leukemia
Use of Cannabinoids in the Treatment of Epilepsy
Use of Cannabinoids in the Treatment of Epilepsy
Use of Cannabinoids in the Treatment of Epilepsy
Use of Cannabidiol in the Treatment of Seizures Associated with Herpes Simplex Virus
Application:
18/005,838 →
Publication:
US US20240033272A1
Use of Cannabidiol in the Treatment of Seizures Associated with Rare Epilepsy Syndromes Related to Genetic Abnormalities
Application:
18/005,841 →
Publication:
US US20230285419A1
Cannabidiol-Type Cannabinoid Compound
(+)-Cis Tetrahydrocannabinol ((+)-Cis-Thc) for Use as a Medicament
Application:
17/771,190 →
Publication:
US US20220387377A1
Use of Cannabidiol Preparations in the Treatment of Temporal Lobe Epilepsy
Application:
17/768,048 →
Publication:
US US20240091241A1
Use of Cannabidiol Preparations in the Treatment of Fragile X Syndrome
Application:
17/770,435 →
Publication:
US US20220378714A1
(-) - Cis Tetrahydrocannabinol ((-) - Cis-Thc) for Use as a Medicament
Application:
17/771,184 →
Publication:
US US20220380334A1
Use of Cannabidiol in Combination with Antibiotics
Application:
17/435,892 →
Publication:
US US20220183997A1
Use of Cannabidiol in the Treatment of Seizures Associated with Rare Epilepsy Syndromes Related to Genetic Abnormalities
Use of Cannabidiol in the Treatment of Seizures Associated with CHRNA4 Mutation
Application:
18/005,868 →
Publication:
US US20230277560A1
Use of Cannabidiol in the Treatment of Seizures Associated with Mutations in the Syngapi Gene
Application:
18/005,848 →
Publication:
US US20230285422A1
Use of Cannabidiol in the Treatment of Seizures Associated with Rare Epilepsy Syndromes Related to Structural Abnormalities of the Brain
Application:
18/006,125 →
Publication:
US US20230372367A1
Use of Cannabidiol in the Treatment of Seizures Associated with Rare Epilepsy Syndromes Related to Genetic Abnormalities
Application:
18/005,847 →
Publication:
US US20230310463A1
Cannabidiol-Type Cannabinoid Compound
Cannabidiol-Type Cannabinoid Compound
Cannabinoid Formulations
Application:
17/406,401 →
Publication:
US US20220211629A1
Use of Cannabidiol in the Treatment of Seizures Associated with Rare Epilepsy Syndromes Related to Genetic Abnormalities
Application:
18/005,843 →
Publication:
US US20230285420A1
Use of Cannabidiol in the Treatment of Seizures Associated with Rare Epilepsy Syndromes Related to Genetic Abnormalities
Application:
18/006,121 →
Publication:
US US20230285426A1
Cannabidivarin Preparations for Use as a Medicament
Application:
17/770,436 →
Publication:
US US20220387350A1
Cannabidiol for Use in the Treatment of Seizures Associated with Rare Epilepsy Syndromes Related to Genetic Abnormalities
Application:
18/005,851 →
Publication:
US US20230285423A1
Cannabidiol-Type Cannabinoid Compound
Use of Cannabidiol in the Treatment of Dravet Syndrome
Application:
17/631,069 →
Publication:
US US20220184000A1
Use of Cannabidiol in the Treatment of Epileptic Spasms
Application:
17/611,824 →
Publication:
US US20220257529A1
Use of Cannabinoids in the Treatment of Epilepsy
Application:
17/426,442 →
Publication:
US US20220023232A1
Use of Cannabinolids in the Treatment of Epilepsy
Application:
17/296,076 →
Publication:
US US20220008355A1
Parenteral Formulations
Use of Cannabidiol in the Treatment of Seizures Associated with Rare Epilepsy Syndromes Related to Brain Injury
Application:
18/006,131 →
Publication:
US US20230310464A1
Use of Cannabidiol in the Treatment of Seizures Associated with Rare Epilepsy Syndromes Related to Genetic Abnormalities
Application:
18/006,133 →
Publication:
US US20230372368A1
Use of Cannabidiol in the Treatment of Seizures Associated with Rare Epilepsy Syndromes Related to Genetic Abnormalities
Application:
18/005,852 →
Publication:
US US20230285424A1
Use of Cannabidiol in the Treatment of Seizures Associated with Rare Epilepsy Syndromes Related to Genetic Abnormalities
Application:
18/005,845 →
Publication:
US US20230285421A1
Use of Cannabidiol Preparations in the Treatment of Absence Epilepsy
Application:
17/771,183 →
Publication:
US US20220378715A1
Use of Cannabinoids in the Treatment of Comorbidities Associated with Epilepsy
Application:
17/424,682 →
Publication:
US US20220226257A1
Use of Cannabidiol in the Treatment of Seizures Associated with Rare Epilepsy Syndromes Related to Structural Abnormalities of the Brain
Use of Cannabidiol in the Treatment of Seizures Associated with Rett Syndrome
Use of Cannabidiol in the Treatment of Tuberous Sclerosis Complex
Use of Cannabidiol in the Treatment of Epilepsy
(+)-Trans Tetrahydrocannabinol ((+)-Trans-Thc) for Use as a Medicament
Application:
17/771,195 →
Publication:
US US20220378738A1
Oral Cannabinoid Formulations
Application:
17/786,949 →
Publication:
US US20230038423A1
Cannabinoid Derivatives as Pharmaceutically Active Compounds and Methods of Preparation Thereof
Cannabinoids in the Treatment of Epilepsy
Application:
17/689,607 →
Publication:
US US20220202738A1
Methods of Treating Tuberous Sclerosis Complex with Cannabidiol and Everolimus
Methods of Treating Tuberous Sclerosis Complex with Cannabidiol and Everolimus
Use of Cannabinoids in the Treatment of Epilepsy
Use of Cannabinoids in the Treatment of Epilepsy
Application:
18/170,235 →
Publication:
US US20240033229A1
Use of Cannabidiol in the Treatment of Epilepsy
Application:
17/853,367 →
Publication:
US US20220323375A1
Use of the Phytocannabinoid Cannabidiol (Cbd) in Combination with a Standard Anti-Epileptic Drug (Saed) in the Treatment of Epilepsy
Pharmaceutical Composition Comprising the Phytocannabinoids Cannabidivarin (Cbdv) and Cannabidiol (Cbd)
Use of Cannabinoids in the Treatment of Epilepsy
Low-Intensity Treatment of Hematological Disorders
Method of Lyophilizing Liposomes
Application:
17/812,414 →
Publication:
US US20230172855A1
Remote Loading of Sparingly Water-Soluble Drugs into Liposomes
Remote Loading of Sparingly Water-Soluble Drugs into Liposomes
Remote Loading of Sparingly Water-Soluble Drugs into Lipid Vesicles
Remote Loading of Sparingly Water-Soluble Drugs into Lipid Vesicles
Inhibiting Ataxia Telangiectasia and RAD3-Related Protein (Atr)
Remote Loading of Sparingly Water-Soluble Drugs into Liposomes
Remote Loading of Sparingly Water-Soluble Drugs Into Lipid Vesicles
Liposomal Formulations of Bcl Inhibitors
Methods and Materials for Treating Neurotoxicity
Application:
17/766,113 →
Publication:
US US20220354834A1
Treating Essential Tremor Using (R)-2-(4-Isopropylphenyl)-N-(1-(5-(2,2,2-Trifluoroethoxy)Pyridin-2-Yl)Ethyl)Acetamide
Patent:
11,311,522 →
Application:
17/313,750 →
Devices and Methods for Facilitating and Controlling Use of a Medication
Gamma-Hydroxybutyrate Compositions and Their Use for the Treatment of Disorders
Application:
17/860,498 →
Publication:
US US20220362185A1
Controlled Release Dosage Forms for High Dose, Water Soluble and Hygroscopic Drug Substances
Treatment of Hematological Disorders
Defibrotide for the Prevention and Treatment of Cytokine Release Syndrome and Neurotoxicity Associated with Immunodepletion
Ras Inhibitors and Methods of Using the Same
Alcohol-Resistant Drug Formulations
Chiral Synthesis of Fused Bicyclic Raf Inhibitors
Application:
17/387,041 →
Publication:
US US20220041595A1
Defibrotide Treatment for the Prevention of Organ Rejection and Injury
Application:
17/918,692 →
Publication:
US US20230086833A1
High Concentration Formulations
Application:
17/377,972 →
Publication:
US US20210338707A1
Subcutaneous Delivery of High Concentration Formulations
Application:
17/311,575 →
Publication:
US US20220023533A1
Delivery of Low Viscosity Formulations
Application:
17/802,795 →
Publication:
US US20230190783A1
Ghb Formulation and Method for Its Manufacture
Application:
18/473,935 →
Publication:
US US20240016770A1
Defibrotide for Use in Preventing and Treating Sepsis
PCT:
PCT/US2023/077630 ↗
Combination Therapies Involving L-Asparaginase
PCT:
PCT/US2023/027665 ↗
Related Assignments
(25)
Other recorded transfers of the patents in this record — the chain of ownership.
Assignment of Assignor's Interest
Aug 17, 2023
From: CRAIG, KEVIN JAMES; CHECKETTS, DANIEL ADAM
To: GW RESEARCH LIMITED
Reel/Frame 064629/0359 →
Assignment of Assignor's Interest
Aug 17, 2023
From: GUY, GEOFFREY; KNAPPERTZ, VOLKER; WHALLEY, BENJAMIN; WOOLLEY-ROBERTS, MARIE
To: GW RESEARCH LIMITED
Reel/Frame 064629/0391 →
Assignment of Assignor's Interest
Sep 13, 2023
From: SILCOCK, ALAN JAMES; MILLET, ANTOINE; TSE, KAREN KA-YEN; HINCHLIFFE, PAUL STUART
To: GW RESEARCH LIMITED
Reel/Frame 064886/0543 →
Assignment of Assignor's Interest
Sep 15, 2023
From: MERRIMACK PHARMACEUTICALS, INC.
To: CELATOR PHARMACEUTICALS, INC.
Reel/Frame 064917/0238 →
Assignment of Assignor's Interest
Sep 15, 2023
From: DRUMMOND, DARYL C.; KIRPOTIN, DMITRI B.; GENG, BOLIN; TIPPARAJU, SURESH K.
To: MERRIMACK PHARMACEUTICALS, INC.
Reel/Frame 064917/0262 →
Assignment of Assignor's Interest
Oct 2, 2023
From: XL-PROTEIN GMBH
To: JAZZ PHARMACEUTICALS IRELAND LIMITED
Reel/Frame 065097/0783 →
Assignment of Assignor's Interest
Oct 2, 2023
From: O'DONNELL, ANNE
To: JAZZ PHARMACEUTICALS IRELAND LIMITED
Reel/Frame 065097/0734 →
Assignment of Assignor's Interest
Oct 2, 2023
From: FRIEDRICH, LARS
To: XL-PROTEIN GMBH
Reel/Frame 065097/0681 →
Assignment of Assignor's Interest
Oct 24, 2023
From: WAN, LEON; GARG, SHYAM; HAUPTSCHEIN, ROBERT; LEGROS, PHILIPPE
To: JAZZ PHARMACEUTICALS, INC.
Reel/Frame 065326/0073 →
Assignment of Assignor's Interest
Oct 26, 2023
From: WAN, LEON; GARG, SHYAM; HAUPTSCHEIN, ROBERT; LEGROS, PHILIPPE
To: CELATOR PHARMACEUTICALS, INC.
Reel/Frame 065354/0108 →
Assignment of Assignor's Interest
Nov 1, 2023
From: TSE, KAREN KA-YEN
To: GW RESEARCH LIMITED
Reel/Frame 065419/0469 →
Assignment of Assignor's Interest
Nov 3, 2023
From: KNAPPERTZ, VOLKER ARMIN; CHECKETTS, DANIEL ADAM
To: GW RESEARCH LIMITED
Reel/Frame 065447/0973 →
Assignment of Assignor's Interest
Nov 29, 2023
From: SILCOCK, ALAN JAMES; TSE, KAREN KA-YEN
To: GW RESEARCH LIMITED
Reel/Frame 065698/0330 →
Assignment of Assignor's Interest
Dec 6, 2023
From: CHECKETTS, DANIEL ADAM; CRAIG, KEVIN JAMES
To: GW RESEARCH LIMITED
Reel/Frame 065784/0901 →
Assignment of Assignor's Interest
Dec 7, 2023
From: CHECKETTS, DANIEL ADAM; CRAIG, KEVIN JAMES
To: GW RESEARCH LIMITED
Reel/Frame 065803/0405 →
Assignment of Assignor's Interest
Dec 7, 2023
From: GUY, GEOFFREY WILLIAM; WRIGHT, STEPHEN
To: GW RESEARCH LIMITED
Reel/Frame 065804/0323 →
Assignment of Assignor's Interest
Dec 7, 2023
From: DEVINSKY, ORRIN
To: GW PHARMA LIMITED
Reel/Frame 065834/0707 →
Assignment of Assignor's Interest
Dec 8, 2023
From: GW PHARMA LIMITED
To: GW RESEARCH LIMITED
Reel/Frame 065837/0072 →
Assignment of Assignor's Interest
Dec 11, 2023
From: WILKHU, JITINDER; BENDER, JOHAN
To: GW RESEARCH LIMITED
Reel/Frame 065831/0664 →
Assignment of Assignor's Interest
Feb 5, 2024
From: BABSON, KIMBERLY
To: JAZZ PHARMACEUTICALS IRELAND LIMITED
Reel/Frame 066383/0388 →
Assignment of Assignor's Interest
Feb 7, 2024
From: TARDI, PAUL; WAN, LEON; GARG, SHYAM MADHUSUDAN; GAO, JUN
To: CELATOR PHARMACEUTICALS, INC.
Reel/Frame 066411/0408 →
Assignment of Assignor's Interest
Apr 2, 2024
From: GUY, GEOFFREY; WRIGHT, STEPHEN; MEAD, ALICE; DEVINSKY, ORRIN
To: GW PHARMA LIMITED
Reel/Frame 066975/0305 →
Asset Purchase by Way of Deed
Apr 2, 2024
From: GW PHARMA LIMITED
To: GW RESEARCH LIMITED
Reel/Frame 066975/0829 →
Assignment of Assignor's Interest
Apr 26, 2024
From: REDX PHARMA PLC
To: JAZZ PHARMACEUTICALS IRELAND LIMITED
Reel/Frame 067240/0743 →
Assignment of Assignor's Interest
Apr 26, 2024
From: JONES, CLIFFORD DAVID; COLLETTO, CHIARA
To: REDX IMMUNOLOGY LTD
Reel/Frame 067239/0380 →